Portal Access – a medical device startup company pioneering next-generation advanced vascular access solutions for oncology – announced the closing of a $7 million Series A financing round today. The funding round was fully subscribed, highlighting strong investor support for the company’s vision and technology. Over 80% of the round was led by U.S physician investors including oncologists, interventional radiologists, cardiologists, vascular surgeons and others, along with a partnership from a U.S based venture capital fund.
How the funding will be used: The funding will support regulatory activities and the planned 510(k) submission for approval to the U.S. Food and Drug Administration (FDA) for Flexi-Port SLF-TANL, a novel subcutaneous port designed to simplify vascular access for oncology patients and a limited market launch. 510(k) submission is expected July 2025 and U.S market launch is anticipated in early 2026. The device is intended to enhance usability, reduce complexity, broaden accessibility and decrease costs.
Despite being the standard of care, it is estimated that about half of cancer patients do not receive a chemo-port due to various reasons like delay in treatment. And by simplifying access and potentially enabling placement in additional care settings, The Flexi-Port SLF-TANL device may help reduce treatment delays, procedural risks, and overall healthcare costs — improving the patient experience and operational efficiency across cancer care delivery.
KEY QUOTES:
“Closing this funding round represents an important milestone as we work toward regulatory approval. Flexi-Port™ SLF-TANL™ is engineered with a focus on simplicity, stability, and scalability — likely to support more efficient workflows in oncology access settings. It’s a solution for both clinicians and patients and created with the most optimal patient outcome and experience in mind.”
Dr. Michael Tal, Founder and CEO of PorTal Access
“I have used the Flexi-Port SLF-TANL to provide chemotherapy in some of the most vulnerable patients and it has consistently exceeded expectations. Its innovative self-tunneling technology is a revolutionary advancement offering a less invasive option that can be placed safely at the bedside or in an outpatient setting. From a clinical perspective, this technology has the potential to transform the standard of care in port placement – offering patients a more dignified, convenient, and compassionate experience at a time when it matters most.”
Matthew Ostroff, RN, MSN, AGACNP, VABC, a pioneer in the field of bedside vascular access
“In my career, I have never witnessed this level of enthusiasm from physicians for a medical technology. During our Series A round, the demand for the Flexi-Port™ SLF-TANL™ was overwhelming—$6 million of our funding came directly from individual physician investors. This type of physician-driven investment is both remarkable and virtually unprecedented. From a market development perspective, the response has been equally compelling. We are seeing significant interest from clinics and hospitals across the country, many of which are already preparing to integrate the Flexi-Port™ SLF-TANL™ into their practice as soon as it becomes available. They’ve been waiting more than 30 years for an innovation like this. Today, we are one step closer to delivering this transformative solution to clinicians and their patients.”
Angela Dotson, Executive VP of Business Development at PorTal Access
